Jessie J. Hsu

Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial

Paolo A. Ascierto, Grant A. McArthur, Brigitte Dréno et al. · The Lancet Oncology · 2016 · 986 citations

Medicine, Advanced Brafv600-mutant Melanoma, Melanoma +7

Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis

Jennifer L. McQuade, Carrie R. Daniel, Kenneth R. Hess et al. · The Lancet Oncology · 2018 · 647 citations · Full text

Oncology, Body Composition, Cancer Management +8

A performance comparison study of ad hoc wireless multicast protocols

Sung-Ju Lee, W. Su, Jessie J. Hsu et al. · 2002 · 480 citations

Multicast Routing Protocols, Wireless Routing, Network Communication Protocol +9

B-cell Lymphomas With Concurrent IGH-BCL2 and MYC Rearrangements Are Aggressive Neoplasms With Clinical and Pathologic Features Distinct From Burkitt Lymphoma and Diffuse Large B-cell Lymphoma

Matija Snuderl, Olga Kolman, Yi‐Bin Chen et al. · The American Journal of Surgical Pathology · 2010 · 353 citations · Full text

Phase III Trial Comparing Concurrent Biochemotherapy With Cisplatin, Vinblastine, Dacarbazine, Interleukin-2, and Interferon Alfa-2b With Cisplatin, Vinblastine, and Dacarbazine Alone in Patients With Metastatic Malignant Melanoma (E3695): A Trial Coordinated by the Eastern Cooperative Oncology Group

Michael B. Atkins, Jessie J. Hsu, Gary I. Cohen et al. · Journal of Clinical Oncology · 2008 · 322 citations · Full text